Psoriasis treatment secukinumab approved by NICE

The monoclonal antibody secukinumab (Cosentyx) has been endorsed by NICE for use in patients with severe plaque psoriasis who have not responded to, or have an intolerance or contraindication to, standard systemic therapies.

Plaque psoriasis is the most common form of the disease and appears as thick and extensive skin lesions (plaques). | iSTOCK
Plaque psoriasis is the most common form of the disease and appears as thick and extensive skin lesions (plaques). | iSTOCK

Secukinumab is recommended as an option for adults with a Psoriasis Area Severity Index (PASI) score of 10 or more and a Dermatology Life Quality Index (DLQI) score greater than 10.

Further information
NICE technology appraisal TA350

Treatment with secukinumab should be stopped if an adequate response is not achieved by 12 weeks. An adequate response is defined as either a 75% reduction in PASI score, or a 50% reduction in PASI score accompanied by a 5-point reduction in DLQI score.

Clinicians may need to adjust the DLQI score if the patient has any disabilities or communication difficulties that could affect the assessment.

NICE's decision is conditional on the manufacturer providing secukinumab with the discount agreed in the patient access scheme.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more